New publication calls for greater research and investment in theranostics

September 15, 2017

Theranostics is the future of precision medicine, according to The Journal of Nuclear Medicine’s September 2017 supplemental issue.

“I do believe that the industry is ready for [theranostics], as AAA has recently shown by picking up 177Lu-DOTATATE, conducting a prospective randomized phase III trial and now waiting for FDA approval,” Dr. Ken Herrmann, co-editor of the supplement and chair of nuclear medicine at the University of Duisburg-Essen, told HCB News. 

Read the full article.